Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial

This randomized, single-blind, placebo-controlled trial evaluated the impact of metformin on longevity-associated pathways in 38 prediabetic individuals over two months. Participants received either metformin (1500 mg/day) or placebo. Metformin treatment led to significant improvements in metabolic parameters and insulin sensitivity. Notably, there was an increase in SIRT1 gene and protein